Cancel
Tim Boire is the CEO and co-founder of VenoStent, known for his leadership in advancing medical technology, including securing FDA approvals and significant financing for clinical trials.
CEO & Co-founder of VenoStent
Tim Boire serves as the CEO and Co-founder of VenoStent. VenoStent is known for its innovative medical technologies and emphasis on improving patient outcomes. As part of the executive management team, Tim plays a crucial role in strategic decision-making and guiding the company's vision. His leadership is integral to the growth and success of VenoStent, steering the company through various developmental stages and market challenges.
Education and Expertise
Tim Boire holds a PhD, which contributes significantly to his expertise and capability in the field of medical technology. This advanced level of education supports his understanding of complex medical challenges and innovative solutions. His academic background provides a strong foundation for his role at VenoStent, where his knowledge is applied to developing cutting-edge technologies and clinical trials.
VenoStent Clinical Trials
Tim Boire was featured in Yahoo Finance for his role in enrolling the first subjects in a 200-subject US clinical trial. This milestone underscores the progress VenoStent has made under his leadership towards validating their medical technology. These trials are crucial for gaining insights and data required for the development and approval of new treatments.
Series A Financing and FDA IDE Approval
Under Tim Boire's leadership, VenoStent successfully completed a $16M Series A financing round. This achievement, reported by Yahoo Finance, provided the necessary funds to advance the company's research and development efforts. Additionally, VenoStent received IDE approval from the FDA to begin a US trial, marking a significant step forward in bringing their technology to market.
Breakthrough Device Designation by FDA
The technology developed by VenoStent received Breakthrough Device Designation from the FDA, as reported by AP. This designation highlights the potential of VenoStent's innovations to provide substantial improvements over existing treatments for serious conditions. Receiving such recognition is a testament to the impact of the technology and the leadership of Tim Boire in navigating the regulatory landscape.
